Review Article

The Proportion of Asymptomatic Cases Among SARS-CoV-2 Infected Patients: A Systematic Review

Abdi Birhanu*, Teka Obsa Feyisa, Getahun Chala
School of Medicine, Haramaya University, Harar, Ethiopia

Email address:
abdibiree@gmail.com (A. Birhanu)
*Corresponding author

To cite this article:
Abdi Birhanu, Teka Obsa Feyisa, Getahun Chala. The proportion of Asymptomatic Cases Among SARS-CoV-2 Infected Patients: a Systematic Review. European Journal of Clinical and Biomedical Sciences. Vol. 6, No. 5, 2020, pp. 84-89. doi: 10.11648/j.ejcbs.20200605.13

Received: August 4, 2020; Accepted: August 21, 2020; Published: September 7, 2020

Abstract: Even though some reports unveiled that coronavirus 2019 (COVID-19) cases can be manifested as asymptomatic, there is limited information on how much these cases are significant. Understanding the possible proportion of asymptomatic cases among confirmed patients might help in re-considering of who should be tested for the SARS-CoV-2 infection. Therefore, this study was aimed to summarize the proportion of asymptomatic cases among SARS-COV-2 infected people since the outbreak of COVID-19. Methods: Different studies were searched from databases (PubMed, Medline) by using searching terms. Finally, all eligible articles were selected by using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009 flow diagram. Results: A total of 14 articles that reported asymptomatic cases of COVID-19 were included in this systematic review. The sample size of the studies was ranged from 8 to 2143. Out of the total cases, the overall proportion of asymptomatic cases was 25.9% that ranged from 3.23% to 78%. This systematic review also summarized that there was 17.6%, 4.8%, and 3.23% to 62.2% of asymptomatic cases among pregnant mothers, children, and the adult general population, respectively. Conclusion and Remarks: This review showed that the proportion of asymptomatic SARS-CoV-2 infected people is high. Hence, to tackle COVID-19, all concerned bodies should strengthen the screening of asymptomatic cases as part of contact tracing efforts.

Keywords: Asymptomatic Cases, COVID-19, Proportion, SARS-COV-2, Systematic Review

1. Introduction

Coronaviruses belong to a large family of single-stranded RNA (ssRNA) viruses that are causative agents of the common cold and severe respiratory infections, which include Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), [1-5]. On December 31, 2019, an outbreak of pneumonia caused by an unknown agent appeared in Wuhan, China [6]. First, the pathogen of the disease was called a novel coronavirus, and now, given the name severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Subsequently, the infection caused by SARS-CoV-2 was officially designated ‘coronavirus disease 2019’ (COVID-19) by World Health Organization (WHO), [7]. As of June 08, 2020, WHO reported that the disease has spread to 213 countries and territories, and caused about 7 million confirmed cases and about 40,000 deaths globally [8].

Different studies revealed that the main ways of SARS-CoV-2 transmission are through droplets and fomites during close unprotected contact between an infected and healthy individual, the familial transmission of 78%-85% [9, 10] and nosocomial [11]. Concerning the stage of transmission, several studies indicated that the virus is transmittable during its incubation and asymptomatic period [12-15]. Even though, different reports showed that some of the SARS-CoV-2 infected individuals are asymptomatic, and the potential sources of the infection, different setups are limited to testing individuals based on predetermined conditions such as clinical symptoms and/or exposure history. On the other hand, Zhu et al stated their doubt that there is unclear evidence of whether asymptomatic infection exists for
COVID-19 [16].

Even if the primary focus to combat COVID-19 is prevention by case isolation, quarantine, and careful infection control, the existence of asymptomatic cases is not aggressively seen at different levels. Therefore, by identifying these gaps, we are interested to conduct a systematic review of the proportion of asymptomatic cases among infected people. Since these asymptomatic cases are playing a significant role in transmitting the virus, providing research-based evidence on the prevalence of cases without any clinical feature may be helpful inputs for preventing and controlling of the SARS-CoV-2 infection timely. Hence, the study was conducted to summarize the proportion of asymptomatic cases among SARS-CoV-2 infected people since the outbreak of COVID-19.

2. Methods

2.1. Protocol

Searching of articles followed the recommendations forwarded by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [17].

![Diagram of PRISMA 2009 Flow for extraction of eligible studies.](image)

2.2. Eligibility Criteria

All peer-reviewed published and pre-print articles that reported asymptomatic cases among confirmed SARS-CoV-2 infection were searched. Regarding the study design and time frame, case series, survey, time series, and retrospective cohort/observational studies conducted from late December 2019 up to May 28, 2020, were included in the study. All of the studies were conducted on human subjects and published in the English language. Concerning the target population, the study included articles conducted on adults, children, pregnant mothers, and health professionals. Reviews, opinions, and letters that did not present the originality of the primary data were excluded.

2.3. Literature Searching Procedure

The literature search was conducted on June 03 to June 09,
2020, using two databases (PubMed, Medline) with the search terms of ['proportion' or percentage' and 'Asymptomatic'] AND ['COVID-19' OR 'COVID-19' OR 'novel coronavirus' OR 'SARS-COV-2' OR 'SARS COV 2']. A total of 1870 studies were retrieved through a thorough search from the two databases by using the date of publications one year. Of retrieved studies, after the full-text screening, 1,309 of the studies were excluded. Finally, out of the left 561 studies, after screening the abstract and full-text of the studies, 14 studies were included in the review.

The studies selected in this systematic review were conducted in China, Japan, America, South Korea, and the European region (Figure 1). We also searched for the references included in the introduction.

## 2.4. Additional Analysis

We have calculated the overall proportion of asymptomatic cases among laboratory-confirmed SARS-COV-2 infected people. The proportion of asymptomatic cases was calculated by using asymptomatic cases of SARS-COV-2 as the numerator and all people who have been positive for SARS-CO-2 as the denominators.

\[ P = \frac{\text{no. of asymptomatic cases}}{\text{total no. of SARS-COV-2 infected people}} \times 100\% \]

Where P stands for proportion.

### 3. Results

Out of 14 selected articles, nine were conducted on adult people, two on pediatrics, one on pregnant mothers, and two on healthcare workers. The total number of patients included in the studies was 3945 that is ranged from 8 to 2143. The studies revealed that out of 3945 laboratory-confirmed SARS-COV-2 infected people, the overall proportion of asymptomatic cases was 739 (18.7%) ranging from 3.23% to 78% (Table 1).

### Table 1. The proportion of asymptomatic cases among laboratory-confirmed SARS-COV-2 infected people from selected fourteen articles between 18 January 2019 and May 28, 2020.

| First author | Time horizon | Country | Sample size (N) | Asymptomatic cases (%) | Study Design | Target population | Reference |
|--------------|--------------|---------|-----------------|------------------------|-------------|-------------------|-----------|
| Chen R. et al | 1 March 2020 | Wuhan, China | 17 | 3 (17.6) | Case series | Pregnant mothers | [18] |
| Chen J. et al | 20 Jan, Feb 6, 2020 | Shanghai, China | 249 | 7 (28) | Retrospective Cohort | Adults | [19] |
| Mizumoto K et al | Before 13, Feb 2020 | Japan | 634 | 35 (16) | Time series | Japan | [20] |
| Gostic K et al | Jan 24-21 Feb, 2020 | European regions | 31 | 111 (31.2) | Survey report | Adults | [21] |
| Xing Y et al | March 12, 2020 | China | 355 | 2 (6.4) | Survey report | Adults | [22] |
| Hasan A et al | March 31, 2020 | China | 62 | 2 (3.23) | Survey | Health Care workers | [23] |
| Li K et al | January 18, February 7, 2020 | China | 2143 | 94 (4.4) | Review | Pediatrics | [24] |
| Day M | April 1, 2020 | China | 78 | 7 (9) | Retrospective Cohort | Adults | [25] |
| Qiu H et al | Jan 17 to March 1, 2020 | China | 166 | 130 (78) | Survey report | Adults | [26] |
| Nishiura H et al | February 4, 2020 | Japan | 36 | 10 (28) | Observational | Children | [27] |
| Arons MM et al | May 28, 2020 | America | 8 | 5 (62.2) | Modeling | Passengers | [28] |
| Kim SE et al | April 28, 2020 | South Korea | 48 | 27 (56%) | Survey | Healthcare workers | [29] |
| Ma Y et al | April 27, 2020 | China | 71 | 10 (14.1%) | Cross-sectional | Adults | [30] |

Regarding the study areas, eight (57.1%) and three (21.4%) studies were conducted in China and Japan respectively, and the remaining three (21.4%) studies were conducted in Europe region, America and South Korea (one study in each area) in the different study settings (Table 2).

### Table 2. The overall proportion of asymptomatic cases among laboratory-confirmed SARS-COV-2 infected people from selected fourteen articles (N=3,945) from January 18, 2019, to May 28, 2020.

| Study area | No. articles | Total sample size | Total asymptomatic cases | The overall proportion of asymptomatic cases |
|------------|--------------|------------------|--------------------------|---------------------------------------------|
| China      | 8            | 2798             | 264                      | 9.4%                                        |
| Japan      | 3            | 997              | 436                      | 43.7%                                       |
| European regions | 1 | 31 | 2 | 6.4% |
| America    | 1            | 48               | 27                       | 56%                                         |
| South Korea | 1            | 71               | 10                       | 14.1%                                       |
| Total      | 14           | 3945             | 739                      | 18.7%                                       |
4. Discussion

This systematic review was aimed at reviewing the proportion of asymptomatic cases among SARS-CoV-2 infected patients. Accordingly, fourteen studies from different countries that fulfilled the eligibility criteria were included. The review showed that the overall proportion of asymptomatic cases was notably high.

The eight studies conducted in China disclosed that 9.4% (ranged from 3.23% to 78%) of SARS-COV-2 infected people were asymptomatic. These studies also reported that the overall proportions of asymptomatic cases among pregnant mothers and children were 17.6% and 4.8% in different corners of China, respectively. The lowest (3.23%) proportion of asymptomatic cases was observed among health care providers after discharged from SARS-CoV-2 hospitalization.

The three studies conducted in Japan showed that out of a total of 997 cases, the overall proportion of asymptomatic cases was 436 (43.7%) that ranged from 31.2% to 62.2% in different settings. Also, a time-series study uncovered that the proportion of asymptomatic cases increased from 16% (before 13 February 2020) to 50% (20 February 2020). The study conducted in the European region found that out of 31 laboratory-confirmed cases, 6.5% were asymptomatic (Tables 1 and 2).

The survey study conducted in America on skilled nurses indicated that out of 48 confirmed cases 27 (56%) were asymptomatic. The cross-sectional study conducted on 71 adult patients in South Korea showed 10 (14.1%) asymptomatic cases.

This systematic review demonstrated that the proportion of asymptomatic cases among SARS-CoV-2 infected people is high. Especially, in China, there was a high proportion of asymptomatic cases that might be due to the attention given to large population detection, contact tracing, and proactive follow-up of any suspected/quarantined people during the incubation period of the virus. This study also revealed that more than 60% of the passengers in Japan were asymptomatic. This high proportion among passengers may be due to that the passengers can be missed from those individuals screened based on symptoms at the portal point. Also, this review indicated that people can be re-infected and become asymptomatic after discharged from the hospital.

Moreover, this systematic review unveiled that all individuals, whether they are children, pregnant mothers, or adults are susceptible to SARS-COV-2 and develop a COVID-19 or become asymptomatic. Furthermore, the review indicated that the degree of asymptomatic cases varies among different countries, different study areas of the same country, and target populations. The factors affecting this variation among the different countries and different areas of the same country are most probably the differences in study size, sample size, and study designs. However, the factor responsible for being asymptomatic among different target populations is in the same and or different counties is uncertain and requires investigation.

5. Conclusion

The review demonstrated that 18.7% of COVID-19 cases were asymptomatic. In conclusion, although further studies are warranted to generate weight of evidence, with the limited shred of information, there are a significant number of asymptomatic SARS-CoV-2 infected people.

6. Recommendation

Since prevention should be a priority in combating COVID19, individuals who had an exposure history should be tested as soon as possible regardless of clinical manifestations. Also, besides testing adults for COVID-19, children and pregnant mothers should not be neglected during massive testing, contact tracing, and hospital visits. Moreover, in every country, entry points should be strictly followed by providing a short time-consuming laboratory diagnosis as much as possible. Furthermore, asymptomatic case identification should be carried out as part of contact tracing effort and prevention measures to contain COVID-19. Finally, we recommend that studies that identify the factors responsible for being asymptomatic among SARS-CoV-2 infected individuals should be conducted.

Abbreviations and Acronyms

| Acronym   | Definition                                      |
|-----------|-------------------------------------------------|
| COVID-19  | Coronavirus Disease 2019                        |
| IL-6:     | Interleukin six                                 |
| MERS:     | Middle East Respiratory Syndrome                |
| PRISMA:   | Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
| SARS:     | Severe Acute Respiratory Syndrome               |
| SARS-CoV-2 | Severe Acute Respiratory Syndrome           |
| WHO:      | World Health Organization                       |

Authors’ Contributions

AB was involved in the study conception, article extraction, analysis, writing, and manuscript drafting. GC and TOF participated in articles extraction, manuscript drafting, and critically editing the manuscript. Finally, all authors read and approved the manuscript to be submitted for publication.

Conflict of Interest Statement

The authors declare that they have no competing interests.

Acknowledgements

It is our great privilege to express our gratitude to Haramaya University College of Health and Medical Sciences for its provision of free internet services.
References

[1] Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, Van Amerongen G, van Riel D, et al. Newly discovered coronavirus as the primary cause of the severe acute respiratory syndrome. The Lancet. 2003; 362 (9380): 263-70.

[2] Drosten C, Günther S, Preiser W, Van Der Werf S, Brodt H-R, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. New England journal of medicine. 2003; 348 (20): 1976-7.

[3] de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, et al. Commentary: Middle East respiratory syndrome coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group. Journal of virology. 2013; 87 (14): 7790-2.

[4] Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. Military Medical Research. 2020; 7 (1): 1-10.

[5] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020; 395 (10223): 507-13.

[6] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine. 2020.

[7] ECDC/PAE. Novel coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK – sixth update 12 March 2020. COVID-19 2020 [cited 2020 25 March].

[8] WHO 2020a. Coronavirus disease 2019 (COVID-19): situation report, 140.

[9] Zhi F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020.

[10] Hu L, Chen S, Fu Y, Gao Z, Long H, Ren H-w, et al. Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Patients in Wuhan, China. medRxiv. 2020.

[11] R L. Risk factors for death from COVID-19 identified in Wuhan patients. Medscape. 2020.

[12] Risk assessment: Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK–eighth update. 2020.

[13] WHO. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020. 2020.

[14] Adhikari SP, Meng S, Wu Y-J, Mao Y-P, Ye R-X, Wang Q-Z, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infectious Diseases of Poverty. 2020; 9 (1): 1-12.

[15] Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). StatPearls [Internet]: StatPearls Publishing; 2020.

[16] Zhu Y, Chen YQ. On a Statistical Transmission Model in Analysis of the Early Phase of COVID-19 Outbreak. Statistics in Biosciences. 2020: 1-17.

[17] Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6 (7): e1000097.

[18] Chen R, Zhang Y, Huang L, Cheng BH, Xia ZY, Meng QT. Safety and efficacy of different anesthetic regimens for parturients with COVID-19 undergoing Cesarean delivery: a case series of 17 patients. Can J Anaesth. 2020; 1-9.

[19] Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect. 2020.

[20] Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020; 25 (10).

[21] Spiteri G, Fielding J, Diercke M, Campese C, Enouf V, Gaymard A, et al. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. Euro Surveill. 2020; 25 (9).

[22] Gostic K, Gomez AC, Mummah RO, Kucharski AJ, Lloyd-Smith JO. Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19. Elife. 2020; 9.

[23] Xing Y, Mo P, Xiao Y, Zhao O, Zhang Y, Wang F. Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China, January to February 2020. Euro Surveill. 2020; 25 (10).

[24] Hasan A, Mehmood N, Fergie J. Coronavirus Disease (COVID-19) and Pediatric Patients: A Review of Epidemiology, Symptomatology, Laboratory and Imaging Results to Guide the Development of a Management Algorithm. Cureus. 2020; 12 (3): e7485.

[25] Li K, Fang Y, Li W, Pan C, Qin P, Zhong Y, et al. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). Eur Radiol. 2020.

[26] Day M. Covid-19: four fifths of cases are asymptomatic, China figures indicate. Bmj. 2020; 369: 1375.

[27] Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2020.

[28] Nishiura H, Kobayashi T, Yang Y, Hayashi K, Miyama T, Yokohama, Japan, 2020. Euro Surveill. 2020.

[29] Gostic K, Gomez AC. Mummah RO, Kucharski AJ, Lloyd-Smith JO. Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19. Elife. 2020; 9.

[30] Xing Y, Mo P, Xiao Y, Zhao O, Zhang Y, Wang F. Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China, January to February 2020. Euro Surveill. 2020; 25 (10).

[31] Hasan A, Mehmood N, Fergie J. Coronavirus Disease (COVID-19) and Pediatric Patients: A Review of Epidemiology, Symptomatology, Laboratory and Imaging Results to Guide the Development of a Management Algorithm. Cureus. 2020; 12 (3): e7485.

[32] Li K, Fang Y, Li W, Pan C, Qin P, Zhong Y, et al. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). Eur Radiol. 2020.

[33] Day M. Covid-19: four fifths of cases are asymptomatic, China figures indicate. Bmj. 2020; 369: 1375.

[34] Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2020.

[35] Nishiura H, Kobayashi T, Yang Y, Hayashi K, Miyama T, Yokohama, Japan, 2020. Euro Surveill. 2020.

[36] Gostic K, Gomez AC. Mummah RO, Kucharski AJ, Lloyd-Smith JO. Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19. Elife. 2020; 9.

[37] Xing Y, Mo P, Xiao Y, Zhao O, Zhang Y, Wang F. Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China, January to February 2020. Euro Surveill. 2020; 25 (10).

[38] Hasan A, Mehmood N, Fergie J. Coronavirus Disease (COVID-19) and Pediatric Patients: A Review of Epidemiology, Symptomatology, Laboratory and Imaging Results to Guide the Development of a Management Algorithm. Cureus. 2020; 12 (3): e7485.
[31] Ma Y, Xu Q-n, Wang F-l, Ma X-m, Wang X-y, Zhang X-g, et al. Characteristics of asymptomatic patients with SARS-CoV-2 infection in Jinan, China. Microbes and Infection. 2020.